BLCO (Bausch + Lomb Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by BLCO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | LAURENCE E PAUL | Director | A | — | — |
| 2026-08-14 | Barbara Trebbi | Director | A | — | — |
| 2026-08-14 | Robert J Chersi | Director | A | — | — |
| 2026-08-12 | Frederick Munsch | SVP, Controller and CAO | Sell | — | — |
| 2026-08-10 | ANDREW C. VON ESCHENBACH | Director | Sell | — | — |
| 2026-08-07 | Frederick Munsch | SVP, Controller and CAO | A | — | — |
| 2026-08-07 | Andrew J. Stewart | President, GPIC | A | — | — |
| 2026-08-07 | BRENT L SAUNDERS | Chairman of the Board and CEO | MIXED | — | — |
| 2026-08-07 | A Robert D Bailey | EVP & Chief Legal Officer | A | — | — |
| 2026-08-07 | Yehia Hashad | EVP of R&D and CMO | A | — | — |
| 2026-08-07 | Luc Bonnefoy | President, Surgical | A | — | — |
| 2026-08-07 | Sam Eldessouky | EVP and CFO | A | — | — |
| 2026-08-07 | A Robert D Bailey | EVP & Chief Legal Officer | A | — | — |
| 2026-08-07 | Luc Bonnefoy | President, Surgical | A | — | — |
| 2026-08-07 | Frederick Munsch | SVP, Controller and CAO | A | — | — |
| 2026-08-07 | Sam Eldessouky | EVP and CFO | A | — | — |
| 2026-08-07 | BRENT L SAUNDERS | Chairman of the Board and CEO | MIXED | — | — |
| 2026-08-07 | Andrew J. Stewart | President, GPIC | A | — | — |
| 2026-08-07 | Yehia Hashad | EVP of R&D and CMO | A | — | — |
| 2026-06-16 | Luc Bonnefoy | President, Surgical | F | — | — |
| 2026-05-28 | Thomas W. Ross Sr. | Director | A | — | — |
| 2026-05-28 | John Paulson | Director | A | — | — |
| 2026-05-28 | ANDREW C. VON ESCHENBACH | Director | A | — | — |
| 2026-05-28 | Karen Ling | Director | A | — | — |
| 2026-05-28 | STEVEN H COLLIS | Director | A | — | — |
| 2026-05-28 | SARAH B KAVANAGH | Director | A | — | — |
| 2026-05-28 | Eduardo Alfonso | Director | A | — | — |
| 2026-05-28 | RUSSEL C ROBERTSON | Director | A | — | — |
| 2026-05-28 | Nathalie D. Bernier | Director | A | — | — |
| 2026-05-26 | BRENT L SAUNDERS | Chairman of the Board and CEO | F | — | — |
| 2026-05-07 | Luc Bonnefoy | President, Surgical | F | — | — |
| 2026-05-07 | Sam Eldessouky | EVP and CFO | F | — | — |
| 2026-05-07 | Frederick Munsch | SVP, Controller and CAO | F | — | — |
| 2026-05-07 | Yehia Hashad | EVP of R&D and CMO | F | — | — |
| 2026-05-01 | John Paulson | Director | A | — | — |
| 2026-05-01 | STEVEN H COLLIS | Director | A | — | — |
| 2026-05-01 | RUSSEL C ROBERTSON | Director | A | — | — |
| 2026-05-01 | Eduardo Alfonso | Director | A | — | — |
| 2026-04-27 | A Robert D Bailey | EVP & Chief Legal Officer | F | — | — |
| 2026-04-27 | Andrew J. Stewart | President, GPIC | F | — | — |
| 2026-03-10 | Sam Eldessouky | EVP and CFO | MIXED | — | — |
| 2026-03-10 | A Robert D Bailey | EVP & Chief Legal Officer | MIXED | — | — |
| 2026-03-10 | BRENT L SAUNDERS | CEO and Chairman of the Board | MIXED | — | — |
| 2026-03-04 | Thomas W. Ross Sr. | Director | MIXED | — | — |
| 2026-03-03 | Eduardo Alfonso | Director | MIXED | — | — |
| 2026-03-03 | ANDREW C. VON ESCHENBACH | Director | MIXED | — | — |
| 2026-03-02 | Andrew J. Stewart | President, GPIC | F | — | — |
| 2026-03-02 | Luc Bonnefoy | President, Surgical | F | — | — |
| 2026-03-02 | BRENT L SAUNDERS | CEO and Chairman of the Board | F | — | — |
| 2026-03-02 | A Robert D Bailey | EVP & Chief Legal Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 310,449,643 | — |
| — | Chairman of the Board and CEO | 974,158 | — |
| — | CEO & Chairman | 472,222 | — |
| — | EVP and CFO | 393,527 | — |
| — | EVP & Chief Legal Officer | 264,241 | — |
| — | EVP of R&D and CMO | 187,350 | — |
| — | Please see remarks | 146,677 | — |
| — | Please see remarks | 125,702 | — |
| — | President, Surgical | 103,801 | — |
| — | President, GPIC | 103,211 | — |
| — | Director | 94,260 | — |
| — | Director | 89,823 | — |
| — | Director | 85,505 | — |
| — | Director | 85,233 | — |
| — | Director | 69,541 | — |
| — | Director | 63,733 | — |
| — | Director | 61,518 | — |
| — | Director | 61,147 | — |
| — | Director | 61,147 | — |
| — | SVP, Controller and CAO | 45,831 | — |
| — | Director | 42,003 | — |
| — | Director | 32,952 | — |
| — | Director | 31,072 | — |
| — | Director | 11,776 | — |
| — | Director | 11,776 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BLCO quote page; the site-wide leaderboard is on the insider transactions hub.